Multiple Myeloma (MM) in First Relapse Patients: Role of the Second Autologous Stem-Cell Trasplant (ASCT): Experience of Two Centers

the 2nd ASCT is considered as a salvage therapy in the 2016 IMWG guidelines for patients with MM in the 1st relapse, provided that the duration of the response to the 1st ASTC is ≥ 18 months. Currently, the increasing effectiveness of the available therapies as 2nd line treatment for MM, could challenge the role of the 2nd ASCT in this setting.